Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of <i>Achromobacter</i> spp. Lung Infection

Both pulmonary tuberculosis (PTB) and coronavirus disease-2019 (COVID-19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of <i>Achromobacter</i> spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID-19. A 63-year-old Cameroonian woman presented in November 2021 with a history of cough with productive muco-purulent sputum, asthenia, headaches, and chest pain for 8 weeks. There was no history of hemoptysis or difficulty in breathing. She was treated for PTB in 2002 and COVID-19 in 2020 and had no other underlying co-morbidities. Chest X-ray showed bronchiectasis in the right lung and features of healed PTB. SARS-CoV-2 antigen, antibody, and real-time polymerase chain reaction tests were negative. Microscopy and GeneXpert MTB/RIF on the sputum sample were both negative. Sputum samples grew <i>Aspergillus flavus</i> complex and <i>Aspergillus niger</i> complex, and serum <i>Aspergillus</i>-specific IgG-IgM antibody was positive, suggestive of CPA. She showed significant clinical improvement on itraconazole tablets 200 mg (every 12 h) after 4 months of therapy. She presented 1 month later with severe symptomatic relapse and elevated white blood cells (27,000 cells/μL). Antibiotic therapy with amoxicillin + clavulanic acid and subsequently with ceftriaxone was unsuccessful. Chest CT scan showed a middle right mediastinal tissue mass with crenulated edges. Bronchoalveolar lavage (BAL) and lung biopsy testing yielded a negative result for PTB, invasive aspergillosis, and lung cancer. However, the BAL sample grew <i>Achromobacter</i> spp. She was initiated on imipenem 1 g (3 g/day × 10 days) with resolution of symptoms. This case suggests that because of the high burden of TB and COVID-19 in Cameroon, pulmonary bacterial and fungal superinfections are underreported. CPA is presently undiagnosed and underreported in Cameroon. Further investigations should be performed in patients not responding to usual antibiotics.

Authors

Institutions

Publication Details

Journal
Clinical Case Reports
Published
2025-10-01
DOI
https://doi.org/10.1002/ccr3.71121
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of Achromobacter spp. Lung Infection

Felix Bongomin, David W. Denning, Marius Paulin Ngouanom Kuate
Clinical Case Reports
Antifungal resistance and susceptibility
article

Chronic Pulmonary Aspergillosis Secondary Infection: A Case Report of Achromobacter spp. Lung Infection

Felix Bongomin, David W. Denning, Marius Paulin Ngouanom Kuate
article en

Abstract

Both pulmonary tuberculosis (PTB) and coronavirus disease-2019 (COVID-19) are risk factors for chronic pulmonary aspergillosis (CPA) and other pulmonary infectious diseases because of residual lung damage. We report a case of <i>Achromobacter</i> spp. infection following CPA in an immunocompetent woman with a history of PTB and COVID-19. A 63-year-old Cameroonian woman presented in November 2021 with a history of cough with productive muco-purulent sputum, asthenia, headaches, and chest pain for 8 weeks. There was no history of hemoptysis or difficulty in breathing. She was treated for PTB in 2002 and COVID-19 in 2020 and had no other underlying co-morbidities. Chest X-ray showed bronchiectasis in the right lung and features of healed PTB. SARS-CoV-2 antigen, antibody, and real-time polymerase chain reaction tests were negative. Microscopy and GeneXpert MTB/RIF on the sputum sample were both negative. Sputum samples grew <i>Aspergillus flavus</i> complex and <i>Aspergillus niger</i> complex, and serum <i>Aspergillus</i>-specific IgG-IgM antibody was positive, suggestive of CPA. She showed significant clinical improvement on itraconazole tablets 200 mg (every 12 h) after 4 months of therapy. She presented 1 month later with severe symptomatic relapse and elevated white blood cells (27,000 cells/μL). Antibiotic therapy with amoxicillin + clavulanic acid and subsequently with ceftriaxone was unsuccessful. Chest CT scan showed a middle right mediastinal tissue mass with crenulated edges. Bronchoalveolar lavage (BAL) and lung biopsy testing yielded a negative result for PTB, invasive aspergillosis, and lung cancer. However, the BAL sample grew <i>Achromobacter</i> spp. She was initiated on imipenem 1 g (3 g/day × 10 days) with resolution of symptoms. This case suggests that because of the high burden of TB and COVID-19 in Cameroon, pulmonary bacterial and fungal superinfections are underreported. CPA is presently undiagnosed and underreported in Cameroon. Further investigations should be performed in patients not responding to usual antibiotics.

Clinical Case ReportsVol. 13(10)
Gulu University (UG), University of Buea (CM), Manchester Academic Health Science Centre (GB), Action for ME (GB), University of Manchester (GB)
American Society of Tropical Medicine and Hygiene
Openalex Percentile: Top 67%
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.